Zodasiran for High Cholesterol

(SPRUCE Trial)

This trial tests a new treatment called zodasiran for individuals with homozygous familial hypercholesterolemia (HoFH), a condition that causes very high cholesterol levels that are difficult to control. The researchers aim to determine if zodasiran can safely lower cholesterol levels more effectively than current treatments. They seek participants aged 12 to 18 with high cholesterol despite medication. Those diagnosed with HoFH and still experiencing high cholesterol levels may find this trial suitable. As a Phase 3 trial, it represents the final step before FDA approval, providing access to a potentially groundbreaking treatment.

Research has shown that zodasiran has been tested in earlier studies to assess its safety in people. Most patients tolerated zodasiran well. While all treatments can have side effects, no serious side effects have been commonly reported for zodasiran in the available data. This suggests that zodasiran might be a safe option for individuals with high cholesterol issues, such as homozygous familial hypercholesterolemia (HoFH), especially when other treatments prove insufficient. However, the current phase of the study involves further investigation to fully confirm these findings.¹²³⁴⁵

Unlike the standard treatments for high cholesterol, which typically include statins and other lipid-lowering drugs, Zodasiran offers a unique approach. It works by targeting RNA molecules involved in cholesterol production, rather than directly interacting with enzymes or receptors like traditional drugs. This innovative mechanism could potentially lead to more effective cholesterol reduction with fewer side effects. Researchers are excited about Zodasiran because it represents a novel strategy in the fight against high cholesterol, possibly offering new hope for patients who don't respond well to existing therapies.

Research has shown that zodasiran, the treatment under study in this trial, may help lower LDL cholesterol, often called "bad cholesterol," in people with homozygous familial hypercholesterolemia (HoFH). In earlier studies, patients taking zodasiran experienced lower levels of LDL-C, ApoB, and non-HDL-C, all crucial for heart health. The treatment also significantly reduced triglycerides, a type of fat in the blood, and remnant cholesterol. Overall, higher doses of zodasiran led to greater reductions in harmful cholesterol levels.⁶⁷⁸⁹¹⁰